NADAC acquisition cost data for FENOFIBRATE 134 MG CAPSULE. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 16714074002 | $0.1545 | 2022-10-19 | Rx |
| 16714074002 | $0.1545 | 2022-10-19 | Rx |
| 16714074002 | $0.1545 | 2022-10-19 | Rx |
| 00115052201 | $0.1328 | 2022-12-21 | Rx |
| 00115052202 | $0.1328 | 2022-12-21 | Rx |
| 13668043901 | $0.1328 | 2022-12-21 | Rx |
| 27241011904 | $0.1328 | 2022-12-21 | Rx |
| 42858013401 | $0.1328 | 2022-12-21 | Rx |
| 43975030510 | $0.1328 | 2022-12-21 | Rx |
| 50268030911 | $0.1328 | 2022-12-21 | Rx |
Generic: Fenofibrate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $113.4M | 2,173,814 | 514,407 | $0.8113 |
| 2020 | $109.5M | 2,080,579 | 499,422 | $0.7909 |
| 2021 | $97.1M | 1,986,086 | 494,615 | $0.7227 |
| 2022 | $84.2M | 1,975,811 | 497,958 | $0.6274 |
| 2023 | $75.0M | 1,979,191 | 500,170 | $0.5674 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $8.5M | 160,855 | 42,874 |
| Florida | $7.7M | 213,053 | 61,580 |
| California | $6.6M | 146,843 | 36,198 |
| Texas | $6.1M | 145,923 | 39,799 |
| Florida | $5.5M | 134,960 | 38,449 |
| Texas | $5.3M | 144,808 | 41,613 |
| New York | $4.7M | 116,761 | 27,413 |
| Pennsylvania | $3.9M | 104,811 | 23,958 |
| New York | $3.8M | 92,209 | 22,702 |
| Ohio | $3.4M | 83,021 | 19,302 |
| Ohio | $3.3M | 86,414 | 20,629 |
| Pennsylvania | $3.3M | 72,460 | 16,845 |
| Illinois | $3.1M | 78,533 | 19,396 |
| Illinois | $3.0M | 67,174 | 16,845 |
| Georgia | $2.7M | 83,621 | 21,703 |
| Michigan | $2.7M | 67,445 | 16,937 |
| California | $2.6M | 57,380 | 13,888 |
| New Jersey | $2.6M | 60,776 | 15,692 |
| North Carolina | $2.3M | 65,886 | 16,507 |
| Georgia | $2.3M | 68,019 | 15,546 |
| Puerto Rico | $2.3M | 81,902 | 19,569 |
| Florida | $2.2M | 50,519 | 14,785 |
| North Carolina | $2.2M | 58,909 | 14,039 |
| Michigan | $2.1M | 56,335 | 14,332 |
| New York | $2.0M | 48,358 | 11,141 |
| New Jersey | $1.9M | 42,106 | 11,112 |
| Alabama | $1.9M | 48,230 | 12,527 |
| Indiana | $1.8M | 44,161 | 10,868 |
| Kentucky | $1.8M | 50,341 | 11,582 |
| Tennessee | $1.8M | 52,899 | 13,864 |
| Missouri | $1.7M | 47,801 | 9,767 |
| Tennessee | $1.7M | 45,251 | 11,251 |
| Virginia | $1.7M | 38,852 | 10,170 |
| Arizona | $1.6M | 46,676 | 13,628 |
| Texas | $1.6M | 39,547 | 11,174 |
| Puerto Rico | $1.6M | 65,885 | 16,264 |
| Indiana | $1.6M | 42,786 | 10,981 |
| Missouri | $1.5M | 47,782 | 10,850 |
| Alabama | $1.5M | 31,069 | 8,005 |
| Kentucky | $1.5M | 44,419 | 10,057 |
| South Carolina | $1.4M | 32,436 | 8,639 |
| South Carolina | $1.3M | 38,336 | 10,236 |
| Virginia | $1.3M | 35,119 | 9,390 |
| Oklahoma | $1.2M | 27,236 | 6,712 |
| Massachusetts | $1.2M | 28,318 | 6,922 |
| Wisconsin | $1.2M | 27,493 | 6,585 |
| Connecticut | $1.1M | 25,205 | 6,160 |
| Wisconsin | $1.1M | 30,829 | 7,587 |
| Louisiana | $1.1M | 36,738 | 8,049 |
| Illinois | $1.0M | 25,004 | 5,648 |
| Maryland | $1.0M | 23,045 | 6,107 |
| Arizona | $1.0M | 25,140 | 7,274 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.